Adding to existing trials in older children, Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have initiated a study of their coronavirus vaccine in children aged 6-12.
With the first children being dosed in the USA, results from the study should be available by the latter part of 2020, with regulatory approval and rollout at the start of next year.
Moderna (Nasdaq: MRNA) has also begun testing its vaccine in children over 12.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze